In a report released on March 17, Nicolas Pauillac from Kepler Capital maintained a Buy rating on COSMO Pharmaceuticals N.V. (0RGI – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback